Perseus Proteomics, Inc. (JP:4882)
:4882
Top Page
Perseus Proteomics, Inc.
(4882)
Select Model
Select Model
Rating:50Neutral
Price Target:
¥233.00
▲(5.91% Upside)
Action:ReiteratedDate:03/10/26
The score is held back primarily by very large ongoing losses and consistent negative operating/free cash flow despite improving versus 2024. Technicals provide some support (price above key moving averages and positive MACD), but the elevated RSI suggests the recent strength may be extended. Valuation is difficult to justify using P/E due to negative earnings and there is no dividend yield data to offset that.
Positive Factors
High gross margins
Consistently very high gross margins indicate strong unit economics and pricing power in the core product set. Over the next 2–6 months this supports margin scalability as revenue grows, giving the company structural leverage to convert incremental sales into profit once fixed costs are controlled.
Negative Factors
Deep ongoing losses
Extremely negative profitability shows the business currently consumes far more resources than it generates, creating a multi-quarter to multi-year path to break-even. Persistent large losses erode equity value, limit reinvestment capacity, and raise the risk that continued funding will be required to sustain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Consistently very high gross margins indicate strong unit economics and pricing power in the core product set. Over the next 2–6 months this supports margin scalability as revenue grows, giving the company structural leverage to convert incremental sales into profit once fixed costs are controlled.
Read all positive factors
Perseus Proteomics, Inc. (4882) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥4.10B
Dividend YieldN/A
Average Volume (3M)226.58K
Price to Earnings (P/E)―
Beta (1Y)1.93
Revenue Growth12.03%
EPS Growth28.11%
CountryJP
Employees25
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)-11.42
Shares Outstanding16,999,600
10 Day Avg. Volume184,610
30 Day Avg. Volume226,583
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.33
Price to Sales (P/S)87.24
P/FCF Ratio-13.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-62.5
Revenue Forecast (FY)¥120.00M
Perseus Proteomics, Inc. Business Overview & Revenue Model
Company Description
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprisin...
Perseus Proteomics, Inc. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 122.98M | 120.38M | 100.40M | 94.20M | 71.93M | 67.95M |
| Gross Profit | 105.51M | 104.05M | 87.69M | 86.53M | 67.75M | 64.10M |
| EBITDA | -820.79M | -826.86M | -891.46M | -692.06M | -478.59M | -415.22M |
| Net Income | -861.71M | -904.80M | -1.10B | -787.00M | -599.02M | -413.22M |
Balance Sheet | ||||||
| Total Assets | 1.65B | 1.82B | 1.69B | 2.57B | 3.30B | 1.12B |
| Cash, Cash Equivalents and Short-Term Investments | 1.51B | 1.67B | 1.54B | 2.44B | 3.21B | 1.07B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 398.55M | 386.43M | 295.46M | 170.10M | 148.38M | 34.91M |
| Stockholders Equity | 1.26B | 1.43B | 1.40B | 2.40B | 3.15B | 1.08B |
Cash Flow | ||||||
| Free Cash Flow | -181.73M | -794.64M | -976.90M | -734.82M | -510.71M | -425.66M |
| Operating Cash Flow | -155.77M | -719.49M | -833.90M | -564.27M | -476.84M | -422.84M |
| Investing Cash Flow | -25.96M | -75.16M | -150.34M | -212.99M | -33.87M | -2.82M |
| Financing Cash Flow | 459.05M | 923.38M | 63.94M | -20.00K | 2.65B | 1.01B |
Perseus Proteomics, Inc. Technical Analysis
Negative
220.00
Price Trends
236.34
Negative
249.72
Negative
304.04
Negative
Market Momentum
-0.03
Negative
49.03
Neutral
56.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4882, the sentiment is Negative. The current price of 220 is below the 20-day moving average (MA) of 229.05, below the 50-day MA of 236.34, and below the 200-day MA of 304.04, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 49.03 is Neutral, neither overbought nor oversold. The STOCH value of 56.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4882.
Perseus Proteomics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ¥7.41B | 22.07 | ― | 4.57% | 6.49% | -32.16% | |
62 Neutral | ¥4.16B | 6.58 | ― | 2.35% | -0.82% | -21.75% | |
56 Neutral | ¥4.45B | -828.32 | ― | ― | -0.77% | -288.43% | |
56 Neutral | ¥17.12B | 120.78 | ― | ― | 1.24% | -33.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥4.10B | -4.91 | ― | ― | 12.03% | 28.11% | |
45 Neutral | ¥6.06B | 169.33 | ― | ― | 17.91% | 77.32% |
* Healthcare Sector Average
JP:4882
Perseus Proteomics, Inc.
241.00
-145.00
-37.56%
JP:2342
Trans Genic Inc.
264.00
79.00
42.70%
JP:3386
Cosmo Bio Co., Ltd.
1,279.00
206.46
19.25%
JP:4978
ReproCELL Inc.
180.00
44.00
32.35%
JP:6090
Human Metabolome Technologies, Inc.
703.00
41.38
6.25%
JP:7707
Precision System Science Co.,Ltd
219.00
33.00
17.74%
Perseus Proteomics, Inc. Corporate Events
Perseus Proteomics Wins AMED Grant to Advance PPMX-T003 for Rare Leukemia
Apr 1, 2026
Perseus Proteomics has secured a JPY 100 million grant under Japan’s FY2026 Drug Discovery Support Promotion Program managed by AMED to advance its antibody candidate PPMX-T003 for aggressive NK-cell leukemia. The funding will support an inv...
Perseus Proteomics Sets FY2026 Forecast, Stays in Red as Licensing Push Continues
Mar 31, 2026
Perseus Proteomics Inc. has issued its previously undetermined full-year earnings forecast for the fiscal year ending March 31, 2026, projecting net sales of 135 million yen and a net loss of 758 million yen, or 50.88 yen per share. The guidance i...
Perseus Proteomics Books Subsidy Income but Suffers Asset Impairment in Q3
Feb 13, 2026
Perseus Proteomics Inc. reported several non-operating items for the first nine months of its fiscal year ending March 2026, including subsidy income of ¥53.3 million, foreign exchange gains of ¥8.8 million, and interest income of ¥...
Perseus Proteomics Narrows Losses but Withholds Full-Year Forecast Amid Ongoing Cash Burn
Feb 13, 2026
Perseus Proteomics reported net sales of ¥103 million for the nine months ended December 31, 2025, a 24.1% year-on-year increase, but remained loss-making with an operating loss of ¥573 million and a net loss of ¥547 million. Basic ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.